ARTV
Artiva Biotherapeutics Inc

792
Mkt Cap
$134.02M
Volume
135,982.00
52W High
$7.36
52W Low
$1.47
PE Ratio
-1.77
ARTV Fundamentals
Price
$5.74
Prev Close
$5.46
Open
$5.54
50D MA
$4.54
Beta
1.35
Avg. Volume
142,591.90
EPS (Annual)
-$2.69
P/B
1.09
Rev/Employee
$2,820.22
$73.79
Loading...
Loading...
News
all
press releases
Artiva Biotherapeutics Pivots to Rheumatoid Arthritis at TD Cowen, Teases 2026 RA Data Update
Artiva Biotherapeutics (NASDAQ:ARTV) used a presentation and fireside chat at TD Cowen's 46th Annual Healthcare Conference to outline its strategy in deep B-cell depletion for autoimmune disease...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Average Recommendation of "Moderate Buy" by Analysts
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) has received an average recommendation of "Moderate Buy" from the six brokerages that are covering the stock, MarketBeat.com reports. One...
MarketBeat·3d ago
News Placeholder
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Short Interest Down 28.5% in January
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) was the recipient of a large decrease in short interest in January. As of January 30th, there was short interest totaling 203,792 shares...
MarketBeat·20d ago
News Placeholder
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Rating of "Moderate Buy" from Brokerages
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) has been given a consensus rating of "Moderate Buy" by the six analysts that are presently covering the stock, Marketbeat.com reports. One...
MarketBeat·28d ago
News Placeholder
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Sees Significant Decline in Short Interest
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) saw a large drop in short interest in January. As of January 15th, there was short interest totaling 284,944 shares, a drop of 27.1% from...
MarketBeat·1mo ago
News Placeholder
Brokers Set Expectations for ARTV FY2030 Earnings
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Analysts at HC Wainwright issued their FY2030 earnings per share estimates for shares of Artiva Biotherapeutics in a research report issued...
MarketBeat·1mo ago
News Placeholder
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Average Recommendation of "Moderate Buy" from Brokerages
Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) have earned a consensus rating of "Moderate Buy" from the six ratings firms that are presently covering the company...
MarketBeat·3mo ago
News Placeholder
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) has been given an average rating of "Moderate Buy" by the six ratings firms that are presently covering the stock, MarketBeat Ratings...
MarketBeat·3mo ago
News Placeholder
Artiva Biotherapeutics (NASDAQ:ARTV) CEO Sells $21,547.50 in Stock
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) CEO Fred Aslan sold 6,375 shares of the business's stock in a transaction on Monday, November 17th. The shares were sold at an average...
MarketBeat·4mo ago
News Placeholder
Fred Aslan Sells 6,375 Shares of Artiva Biotherapeutics (NASDAQ:ARTV) Stock
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) CEO Fred Aslan sold 6,375 shares of the stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average...
MarketBeat·4mo ago
<
1
2
...
>

Latest ARTV News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.